Display options
Cite
Wieding JU, Hellstern P, Köhler M. Inactivation of viruses in fresh-frozen plasma. Ann Hematol. 1993;67(6):259-66doi: 10.1007/BF01696345.
Wieding, J. U., Hellstern, P., & Köhler, M. (1993). Inactivation of viruses in fresh-frozen plasma. Annals of hematology, 67(6), 259-66. https://doi.org/10.1007/BF01696345
Wieding, J U, et al. "Inactivation of viruses in fresh-frozen plasma." Annals of hematology vol. 67,6 (1993): 259-66. doi: https://doi.org/10.1007/BF01696345
Wieding JU, Hellstern P, Köhler M. Inactivation of viruses in fresh-frozen plasma. Ann Hematol. 1993 Dec;67(6):259-66. doi: 10.1007/BF01696345. PMID: 8280811.
Copy Download .nbib Format: NLM
Share it on

Ann Hematol. 1993 Dec;67(6):259-66. doi: 10.1007/BF01696345.

Inactivation of viruses in fresh-frozen plasma.

Annals of hematology

J U Wieding, P Hellstern, M Köhler

Affiliations

  1. Department of Transfusion Medicine, University Hospital, Göttingen, Germany.

PMID: 8280811 DOI: 10.1007/BF01696345

Abstract

Methylene blue (MB) or solvent/detergent (SD) treatment is used for the inactivation of lipid-enveloped viruses in plasma. One important characteristic of the SD treatment is the necessity to pool plasma from different donors, thus inducing the risk of spreading infectious particles. MB treatment can be applied to single-donor plasma, causing no greater infectious risk than conventional fresh-frozen plasma (FFP). However, the virucidal efficacy of the SD method regarding HIV, HBV and HCV has been significantly better examined and proven than the MB treatment. Most of the therapeutic constituents of both plasma products are well maintained; coagulation factors decrease by roughly 5-20%. SD treatment reduces protein S and alpha 2-antiplasmin by approximately 40%, whereas MB treatment leads to a significant photooxidative alteration of fibrinogen with a disturbance of fibrin polymerization. As current studies show, the use of either plasma product is obviously not limited by acute or chronic toxicity. Several studies are in progress to evaluate the relevance of alterations in FFP quality which may affect the clinical efficacy of virus-inactivated plasma.

References

  1. Blood Cells. 1992;18(1):75-88; discussion 88-9 - PubMed
  2. Transfusion. 1992 Jul-Aug;32(6):541-7 - PubMed
  3. Vox Sang. 1990;59(3):129-35 - PubMed
  4. Transfusion. 1991 Jan;31(1):32-9 - PubMed
  5. Thromb Haemost. 1990 Apr 12;63(2):312-5 - PubMed
  6. Transfus Med Rev. 1987 Dec;1(3):201-4 - PubMed
  7. Lancet. 1988 Nov 19;2(8621):1159-62 - PubMed
  8. Blood Rev. 1988 Sep;2(3):206-10 - PubMed
  9. Blood. 1992 Feb 1;79(3):826-31 - PubMed
  10. Lancet. 1992 Mar 28;339(8796):819 - PubMed
  11. Infusionsther Transfusionsmed. 1992 Apr;19(2):91-4 - PubMed
  12. Transfusion. 1985 Nov-Dec;25(6):516-22 - PubMed
  13. Transfus Med Rev. 1991 Jan;5(1):18-32 - PubMed
  14. Vox Sang. 1992;63(3):178-85 - PubMed
  15. Photochem Photobiol. 1966 Mar;4(2):159-70 - PubMed
  16. Eur J Epidemiol. 1987 Jun;3(2):103-18 - PubMed
  17. Thromb Haemost. 1990 Oct 22;64(2):336-7 - PubMed
  18. Transfus Med Rev. 1990 Jan;4(1):35-46 - PubMed
  19. Vox Sang. 1992;62(1):12-20 - PubMed
  20. Transfusion. 1991 Feb;31(2):102-8 - PubMed
  21. Transfusion. 1991 Jul-Aug;31(6):483-90 - PubMed
  22. Vox Sang. 1991;60(4):207-13 - PubMed
  23. Arch Pathol Lab Med. 1990 Mar;114(3):335-40 - PubMed
  24. Vox Sang. 1992;63(4):251-6 - PubMed
  25. Curr Stud Hematol Blood Transfus. 1989;(56):9-22 - PubMed
  26. Ann Hematol. 1992 Nov;65(5):224-8 - PubMed
  27. Biotechnology. 1991;19:417-30 - PubMed
  28. Infusionsther Transfusionsmed. 1992 Apr;19(2):84-90 - PubMed
  29. Lancet. 1992 Dec 12;340(8833):1465-6 - PubMed
  30. Blood Coagul Fibrinolysis. 1993 Aug;4(4):599-604 - PubMed
  31. Nucleic Acids Res. 1990 Feb 11;18(3):631-5 - PubMed
  32. Transfusion. 1994 Feb;34(2):185-6 - PubMed
  33. Infusionsther Transfusionsmed. 1993 Jun;20 Suppl 2:16-8 - PubMed
  34. JAMA. 1985 Jan 25;253(4):551-3 - PubMed

Substances

MeSH terms

Publication Types